Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
118 trials
Recruiting nowPhase 2
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Recruiting nowPhase 1
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting nowPhase 1
THE-0504 in Patients With Solid Tumors
Recruiting nowNot phased
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
Recruiting nowPhase 2
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Recruiting nowNot phased
THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy
Recruiting nowNot phased
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Recruiting nowPhase 1
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Recruiting nowPhase 1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Recruiting nowPhase 1
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Recruiting nowNot phased
A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity
Recruiting nowNot phased
Non-operative Management for Locally Advanced Rectal Cancer
Recruiting nowPhase 2
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
Recruiting nowPhase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Recruiting nowPhase 1
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors